Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05224336 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Psilocybin-assisted Therapy for Phantom Limb Pain

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Sponsor refiled this as active, not recruiting (was completed) Completion date: Mar 7, 2024 to Apr 30, 2031 · Eligibility criteria expanded, about 51 words · Secondary endpoints: details revised at 1 of 3 entries Show 3 more changesShow less
    • Completion date: Mar 7, 2024 to Apr 30, 2031
    • Eligibility criteria expanded, about 51 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Trial status: Recruiting to Completed Enrollment target: estimated 20 to confirmed 10 · Study completion date changed from estimate of Dec 31, 2026 to Mar 7, 2024 · Site details revisedv5 Show 3 more changesShow less
    • Enrollment target: estimated 20 to confirmed 10
    • Study completion date changed from estimate of Dec 31, 2026 to Mar 7, 2024
    • Site details revised
  3. Start date: Jan 1, 2022 to Oct 3, 2022 Primary completion date changed from estimate of Jun 1, 2024 to Mar 7, 2024 · Completion date: Jun 1, 2024 to Dec 31, 2026 · Site contact updatedv4 Show 3 more changesShow less
    • Primary completion date changed from estimate of Jun 1, 2024 to Mar 7, 2024
    • Completion date: Jun 1, 2024 to Dec 31, 2026
    • Site contact updated
  4. Primary completion date: Mar 1, 2023 to Jun 1, 2024 Completion date: Jul 1, 2023 to Jun 1, 2024v3 Show 1 more changeShow less
    • Completion date: Jul 1, 2023 to Jun 1, 2024
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 1, 2022 to Jan 1, 2022 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 1, 2022 to Jan 1, 2022
    • Site details revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on pain symptoms and other moods, attitudes, and behaviors. The investigators' primary hypotheses are that psilocybin is safe to administer in people with PLP and that it will reduce scores on measures of pain. The investigators will also assess a number of secondary measures related to the behavioral and neural responses to pain after psilocybin treatment.
Trial Details
NCT Number NCT05224336
Lead Sponsor University of California, San Diego
Conditions Phantom Limb Pain
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov